Volume 26, Issue 4 , Pages 386-391, July 2008
Phospholipase-C gamma-1 (PLCγ-1) is critical in hepatocyte growth factor induced in vitro invasion and migration without affecting the growth of prostate cancer cells
Abstract
Background
Phospholipase C gamma-1 (PLCγ-1) is an intracellular signalling molecule regulating a number of biological processes including transporter mechanisms, transcription factors, and scaffolding proteins mediating cytoskeleton and membrane trafficking. Hepatocyte growth factor (HGF) is a pleiotrophic factor and a mediator of metastatic spread. This study sought to determine the effect of HGF on the invasive and migratory potential of prostate cancer cells targeted by a ribozyme transgene to PLCγ-1.
Methods
A ribozyme transgene consisting of hammerhead ribozyme and antisense specific to PLCγ-1 was cloned into a PEF6 expression vector and transfected into PC-3 cells. RT-PCR and Western blotting confirmed knock down of PLCγ-1. In vitro invasion and a cytodex-2 bead motility assays with in vitro and in vivo growth models were used to assess the impact of PLCγ-1 manipulation.
Results
PC-3 cells stably transfected with PLCγ-1 ribozyme transgene (PC-3ΔPLCγ) manifested a reduction of PLCγ-1 expression at mRNA/protein levels. HGF/SF increased invasiveness (P < 0.01) and motility (P < 0.0001) of PC-3WT and PC-3PEF6 cells. In contrast, PLCγ-1 knock down PC-3ΔPLCγ cells had reduced invasiveness (P < 0.05) and motility (P < 0.01) compared with PC-3WT and PC-3PEF6 cells. Although there was a marginal change of cell growth in vitro, there was no difference in the rate of growth between PC-3ΔPLCγ, PC-3WT, and PC-3PEF6 cells.
Conclusion
Targeting PLCγ-1 by way of a hammerhead ribozyme to PLCγ-1 is an effective method in reducing invasive phenotype of prostate cancer. PLCγ-1 is a signalling intermediate that has prime influence on HGF induced cellular invasion and migration without affecting the growth of the cells.
Keywords: Ribozyme, HGF/SF, PLCγ-1, Prostate cancer, Migration, Invasion
To access this article, please choose from the options below
PII: S1078-1439(07)00186-X
doi:10.1016/j.urolonc.2007.06.003
© 2008 Elsevier Inc. All rights reserved.
Volume 26, Issue 4 , Pages 386-391, July 2008
